Stay updated on Adjunctive Pimavanserin in Major Depressive Disorder Clinical Trial
Sign up to get notified when there's something new on the Adjunctive Pimavanserin in Major Depressive Disorder Clinical Trial page.

Latest updates to the Adjunctive Pimavanserin in Major Depressive Disorder Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record provides details of the completed Phase 2 pimavanserin study for major depressive disorder, including its eligibility criteria, locations, study design, and measured outcomes. It also includes study documents, results-related dates, and publications.SummaryDifference62%

- Check15 days agoChange DetectedThe site footer now identifies the website release as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide notice announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” in some content.SummaryDifference1%

- Check29 days agoChange DetectedThe site's footer revision identifier updates from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a new Revision: v3.7.0 tag. A large set of study documents and related entries (e.g., Statistical Analysis Plan, Study Protocol, IPD plans, and provider details) were removed from the Study Documents section, changing the accessibility of key materials for the trial.SummaryDifference18%

Stay in the know with updates to Adjunctive Pimavanserin in Major Depressive Disorder Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjunctive Pimavanserin in Major Depressive Disorder Clinical Trial page.